Global Specimen Solutions is excited to work with Covance to strengthen its support for clinical development and translational science by providing live, regulatory-compliant views into specimens and assay data as they are generated during clinical trials
Raleigh, NC (PRWEB) October 13, 2016
Global Specimen Solutions (GSS) today announced a five-year strategic alliance with Covance, the drug development business of Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH). Covance’s market-leading central laboratory will offer GSS products GlobalCODE® and snapTRACK™ to its pharmaceutical and biotechnology clients to provide streamlined global specimen tracking, as well as informed consent and assay result management that will deliver actionable insights from specimens across development programs. Covance will be the exclusive lab to offer GSS's services for pharmaceutical development.
GlobalCODE® is a proprietary pipeline data management system and snapTRACK™ is its companion point-of-collection specimen-tracking mobile application. Together, these technologies support translational medicine, clinical teams and assay owners with live data, analytics and enhanced specimen-tracking capabilities to improve the drug development process. Covance clients will be able to utilize both offerings to record, track and access data and analytics from one unified interface throughout the drug development process.
“Global Specimen Solutions is excited to work with Covance to strengthen its support for clinical development and translational science by providing live, regulatory-compliant views into specimens and assay data as they are generated during clinical trials,” said Amelia Wall Warner, Founder and CEO, Global Specimen Solutions, Inc.
Through the use of GlobalCODE®, clinical trial sponsors will have access to comprehensive views of trial data and biomarkers across populations and time, providing unique insights into performance and test results. Sponsors will also have access to snapTRACK™, an enhanced tool that will allow them to locate their samples at any point in time, recording a detailed chain of custody.
“Our collaboration with GSS enables our clients to track their samples end to end with informed consent management and to see truly unified views of their biomarker data for the first time—bridging data gaps and silos. This will allow better decision-making and insights from the diverse inventory of samples collected across indications over time. This collaboration will help fulfill our mission to improve health and lives by bringing innovative medicines to patients faster,” commented Paul Kirchgraber, M.D., M.B.A., vice president and global general manager for Covance Central Laboratory Services.
For more information about Global Specimen Solutions, visit GlobalSpecimenSolutions.com.
About Global Specimen Solutions, Inc.
Global Specimen Solutions, Inc. provides innovative pipeline data management and analytics solutions and services designed to optimize drug development. GSS was founded in 2013 by global specimen management experts with extensive big pharmaceutical experience. A specialized Clinical Research Organization (CRO) delivering Good Clinical Practice (GCP) accredited products and services, GSS works with clients designing and managing specimen collections with accompanying metadata—from planning to protocol, collection to management, all real-time accessible via targeted analytics and reporting. GSS serves pharmaceutical, biopharma and diagnostic companies and academic institutions. GSS is WBENC certified and a Women & Minority-Owned Business. Headquarters are in Raleigh, North Carolina.